Mazdutide

IBI362

Add to protocol

Build with Mazdutide

Compare prices

Pharmacies & vendors

Calculate dosing

Reconstitution

Overview

Mazdutide is a dual GLP-1 / glucagon receptor agonist developed by Innovent/Eli Lilly. Phase III trials for obesity and type 2 diabetes in China.

Mechanism of Action

Co-agonism of GLP-1R and GCGR produces additive weight-loss effects — GLP-1 suppresses appetite and slows gastric emptying while glucagon agonism increases energy expenditure.

Research Summary

Phase III GLORY-1 trial (2024) reported ~14% placebo-adjusted weight loss at 48 weeks. Approval expected in China 2025.

Dosing Information

Typical Dose

3–9 mg

Frequency

Weekly

Route

SubQ

Notes

Titrated up over 12–20 weeks. Research chemical outside clinical trials.

Reported Side Effects

Nausea
Vomiting
Diarrhea
Decreased appetite

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2
Pregnancy

Track your Mazdutide protocol

Build a protocol with Mazdutide, schedule blood work for key biomarkers, and track your results.

Build Protocol with Mazdutide

This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.